Consolidated Financial Statements March 31, 2022



Independent auditor's report

To the Members of The Children's Hospital Foundation of Manitoba, Inc.

Our opinion

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of The Children's Hospital Foundation of Manitoba, Inc. and its subsidiaries (together, the Foundation) as at March 31, 2022, and the results of its operations and its cash flows for the period from January 1, 2021 to March 31, 2022 in accordance with Canadian accounting standards for not-for-profit organizations.

What we have audited

The Foundation's consolidated financial statements comprise:

- the consolidated statement of financial position as at March 31, 2022;
- the consolidated statement of operations and changes in fund balances for the 15-month period from January 1, 2021 to March 31, 2022;
- the consolidated statement of cash flows for the 15-month period from January 1, 2021 to March 31, 2022; and
- the notes to the consolidated financial statements, which include significant accounting policies and other explanatory information.

Basis for opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the consolidated financial statements* section of our report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We are independent of the Foundation in accordance with the ethical requirements that are relevant to our audit of the consolidated financial statements in Canada. We have fulfilled our other ethical responsibilities in accordance with these requirements.

PricewaterhouseCoopers LLP One Lombard Place, Suite 2300, Winnipeg, Manitoba, Canada R3B 0X6 T: +1 204 926 2400, F: +1 204 944 1020

"PwC" refers to PricewaterhouseCoopers LLP, an Ontario limited liability partnership.



Responsibilities of management and those charged with governance for the consolidated financial statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Foundation's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Foundation or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Foundation's financial reporting process.

Auditor's responsibilities for the audit of the consolidated financial statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.



- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Foundation's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Foundation to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Foundation to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Pricewaterhouse Coopers LLP

Chartered Professional Accountants

Winnipeg, Manitoba June 7, 2022

Consolidated Statement of Financial Position

	March 31, 2022 \$ (note 2)	December 31, 2020 \$
Assets		
Current assets Cash Short-term investments (note 4) Accounts receivable Prepaid expenses Inventory	5,931,894 227,270 292,139 260,503 12,942	3,846,232 267,471 1,335,332 121,862 37,986
	6,724,748	5,608,883
Investments (note 4)	36,216,006	34,079,648
Capital assets (note 5)	9,561,498	10,289,843
	52,502,252	49,978,374
Liabilities		
Current liabilities Accounts payable and accrued liabilities (note 6) Grants payable Deferred revenue	1,646,388 5,835,813 89,593	1,334,001 6,386,216 -
	7,571,794	7,720,217
Fund Balances		
Unrestricted Operating Fund	3,905,141	3,362,815
Externally restricted Endowment Fund Designated Fund	6,005,007 13,157,084	5,507,392 10,657,074
Internally restricted Child Health Research Fund (note 7) Children's Hospital Fund Funds Invested in Capital Assets (note 8)	9,936,958 2,364,770 9,561,498	9,950,440 2,490,593 10,289,843
	44,930,458	42,258,157
	52,502,252	49,978,374
Commitments (note 12)		

Approved by the Board of Directors

_ Chair

Holmes 1 chael

Michael Holmes

Vice-Chair

ZoëRichardson

The accompanying notes are an integral part of these consolidated financial statements.

The Children's Hospital Foundation of Manitoba, Inc. Consolidated Statement of Operations and Changes in Fund Balances

							15-month period ended March 31, 2022 (note 2)	Year ended December 31, 2020
	Unrestricted	Extern	ally restricted		Interr	nally restricted		
	Operating Fund \$	Endowment Fund \$	Designated Fund \$	Child Health Research Fund \$	Children's Hospital Fund \$	Funds Invested in Capital Assets \$	Total \$	Total \$
Revenue Donations and fundraising revenue Lottery proceeds Other revenue (note 10) Investment income (note 4)	6,090,985 757,574 274,839 1,799,141	71,354 - - 604,807	6,675,092 - -	- 1,067,891 -	- - -	- - -	12,837,431 757,574 1,342,730 2,403,948	8,959,818 682,982 1,440,965 3,123,669
	8,922,539	676,161	6,675,092	1,067,891	-	-	17,341,683	14,207,434
Expenses Administrative expenses Fundraising Direct expenses Indirect expenses	1,441,782 1,029,395 1,454,163	34,847 - -	-	-	-	-	1,476,629 1,029,395 1,454,163	1,120,947 1,007,294 1,092,950
	3,925,340	34,847	-	-	-	-	3,960,187	3,221,191
Disbursements and granting activities Amortization Disbursements Grants to Children's Hospital Grants in aid of research	3,622,102	- 20,826 19,995	4,018,862 604,278	- - 1,067,891	125,823	1,229,418 - - -	1,229,418 - 4,165,511 5,314,266	954,860 17,942 4,238,999 4,077,752
	3,622,102	40,821	4,623,140	1,067,891	125,823	1,229,418	10,709,195	9,289,553
Excess (deficiency) of revenue over expenses	1,375,097	600,493	2,051,952	-	(125,823)	(1,229,418)	2,672,301	1,696,690
Fund balances – Beginning of year	3,362,815	5,507,392	10,657,074	9,950,440	2,490,593	10,289,843	42,258,157	40,561,467
Investment in capital assets Interfund transfers (note 11)	(501,073) (331,698)	(102,878)	- 448,058	(13,482)	-	501,073 -	-	-
Fund balances – End of year	3,905,141	6,005,007	13,157,084	9,936,958	2,364,770	9,561,498	44,930,458	42,258,157

The accompanying notes are an integral part of these consolidated financial statements.

	15-month period ended March 31, 2022 \$ (note 2)	Year ended December 31, 2020 \$
Cash provided by (used in)		
Operating activities Excess of revenue over expenses Items not affecting cash Amortization Change in realized and unrealized gains on investments – net	2,672,301 1,229,418 (2,382,660)	1,696,690 954,860 (3,099,487)
Change in realized and direalized gains on investments – net		· · ·
Change in non-cash working capital items	1,519,059 <u>781,173</u> 2,300,232	(447,937) <u>313,112</u> (134,825)
Investing activities		
Redemption of investments – net Purchase of capital assets	286,503 (501,073)	234,419 (141,253)
	(214,570)	93,166
Increase (decrease) in cash during the year	2,085,662	(41,659)
Cash – Beginning of year	3,846,232	3,887,891
Cash – End of year	5,931,894	3,846,232

The accompanying notes are an integral part of these consolidated financial statements.

Notes to Consolidated Financial Statements

March 31, 2022

1 Purpose of the organization

The Children's Hospital Foundation of Manitoba, Inc. (the Foundation) is an independent agency whose purpose is to raise and distribute funds for the advancement of knowledge and care in the fields of child health and child health research and thereby contribute to the improved health of children everywhere.

The Foundation is a registered charity under the Income Tax Act (Canada) and accordingly is exempt from income taxes.

2 Basis of presentation

These consolidated financial statements are prepared in accordance with Canadian accounting standards for not-for-profit organizations (ASNPO).

These consolidated financial statements include the assets and liabilities and results of operations of the Foundation and Children's Hospital Research Institute of Manitoba, Inc. (the Institute) and Children's Hospital Book Market, Inc. (the Book Market), both of which are organizations under the Foundation's common control.

In March 2021, the Foundation's Board of Directors approved a change to the Foundation's year-end from December 31 to March 31. These financial statements represent the first complete fiscal period subsequent to this direction. The current fiscal period includes the 15 months ended March 31, 2022, with comparative financial statements for the 12 months ended December 31, 2020.

3 Summary of significant accounting policies

Fund accounting

For financial reporting purposes, the accounts have been classified into the following funds:

The *Operating Fund* accounts for the Foundation's fundraising and administrative activities. This fund reports unrestricted resources.

The *Endowment Fund* reports resources contributed as endowment capital. Contributions to the Endowment Fund are invested by the Foundation in accordance with its Statement of Investment Policies, whereby, the capital of the Fund will be maintained, and the annual income earned will be allocated and added to the endowment capital to support the desired research, equipment and program funding, based on the restrictions imposed by contributors of the endowment.

The *Designated Fund* is to be used for the purchase of equipment as well as to provide funds for pediatric education and research.

The *Child Health Research Fund* is comprised of several subsidiary funds established for the purpose of supporting pediatric research:

• The Pediatric Research Fund is to be used for pediatric research purposes.

Notes to Consolidated Financial Statements

March 31, 2022

- The *Research Facilities Building Fund* was established for the construction and maintenance of the Foundation's interest in the John Buhler Research Centre.
- The *Research Facilities Equipment Fund* was established to support the purchase and maintenance of research equipment needs of the Foundation's interest in the John Buhler Research Centre.

The *Children's Hospital Fund* was established with funds from the Children's Hospital to be used for future program needs and purchases of equipment for the hospital.

The *Funds Invested in Capital Assets* reports the Foundation's investment of resources in long-term capital assets.

Cash

Cash consists of cash on hand and cash held at banking institutions.

Inventory

Inventory is valued at the lower of invoice cost and net realizable value.

Investments

Current investments consist of guaranteed investment certificates (GICs), which have a maturity date within the next fiscal year, and other short-term liquid investments.

Long-term investments consist of pooled funds with unrealized gains and losses, dividends and interest included in investment income of the appropriate fund. Purchases and sales of investments are recognized using trade date accounting. Management fees attributable to the investments are included in administrative expenses.

Capital assets

Purchased capital assets are recorded at original cost. Contributed capital assets are recorded at fair value at the date of contribution. Amortization is provided on a straight-line basis over the useful lives of the assets as follows:

Office and research equipment	5 years
Computer equipment	3 years
Office furniture	10 years
Leasehold improvements	10 years
Research facility improvements	10 years
Research building	25 years

In the year of acquisition, amortization is taken on half of the original cost.

Notes to Consolidated Financial Statements

March 31, 2022

Revenue recognition

The Foundation follows the restricted fund method of accounting for revenue. Unrestricted contributions are recognized as revenue of the Operating Fund in the year received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured. Restricted contributions are recognized as revenue of the appropriate restricted fund when received. Revenue from the sale of goods is recognized at the time of sale. Investment income is recognized when earned and allocated to certain funds at the discretion of the Board of Directors (the Board).

Government grants

Government grants are recognized when there is reasonable assurance that the Company has complied with the conditions associated with the relevant government program and are recognized in other revenue.

Research grants

The entire amount of research grants to qualified recipients is reflected as an expense in the fiscal year in which the grants are approved and committed.

Contributed services

Volunteers are an integral part of carrying out the activities of the Foundation. Contributed services are not recognized in the consolidated financial statements due to the difficulty in determining fair market value.

Interfund transfers

The transfer of funds between unrestricted and internally restricted funds is based on the term's of reference for each of the Funds and is approved by the Board where applicable.

Allocation of expenses

Certain administrative expenses are allocated to fundraising activities and disbursements and granting activities based upon the proportionate amount of time spent on those functions.

Use of estimates

The preparation of consolidated financial statements in conformity with Canadian ASNPO requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Notes to Consolidated Financial Statements

March 31, 2022

The outbreak of the novel strain of coronavirus, specifically identified as COVID-19, was declared a global pandemic by the World Health Organization in March 2020, which resulted in governments worldwide enacting emergency measures to combat the spread of the virus. These measures, which included the implementation of travel bans, self-imposed quarantine periods and social distancing, have caused material disruption to businesses and the global economy. Governments and central banks have reacted with significant monetary and fiscal interventions designed to stabilize economic conditions. The impact of the pandemic is still uncertain and dependent on the progression of the virus and measures taken by governments and individuals. The Foundation will continue to assess and monitor the impact on its assets and liabilities reported in the consolidated financial statements.

Financial instruments

Financial assets and financial liabilities are initially recognized at fair value and subsequently measured at amortized cost, except for investments in equity instruments that are quoted in an active market, which are measured at fair value. Changes in fair value are recognized in the consolidated statement of operations and changes in fund balances in the year incurred.

Financial assets measured at amortized cost include cash, accounts receivable and short-term investments.

Financial liabilities measured at amortized cost include research grants payable, accounts payable and accrued liabilities.

Financial assets measured at fair value include investments in pooled funds and other equity investments with fair value determined by reference to the latest closing transactional net asset value of each respective pooled fund.

Financial assets are tested for impairment at the end of each reporting period when there are indications that the assets may be impaired.

4 Investments

	15-month period ended March 31, 2022 \$ (note 2)	Year ended December 31, 2020 \$
Short-term Mutual funds GICs	199,219 28,051	6,366 261,105
	227,270	267,471
Long-term Pooled funds	36,216,006	34,079,648

Notes to Consolidated Financial Statements

March 31, 2022

Included in investment income is the following:

			15-month period ended March 31, 2022 \$ (note 2)	Year ended December 31, 2020 \$
	Operating Fund \$	Endowment Fund \$	Net \$	Net \$
Realized and unrealized gains on investments Investment income	1,777,391 21,750	- 604,807	1,777,391 626,557	2,637,088 486,581
	1,799,141	604,807	2,403,948	3,123,669

5 Capital assets

			15-month period ended March 31, 2022 \$ (note 2)	Year ended December 31, 2020 \$
	Cost \$	Accumulated amortization \$	Net \$	Net \$
Office and computer equipment Office furniture Leasehold improvements Research equipment Research computer equipment Research facility improvements Research building	335,651 420,251 614,261 4,002,827 479,008 1,421,443 20,702,195	(256,054) (139,627) (220,400) (3,951,589) (479,008) (1,421,443) (11,946,017)	79,597 280,624 393,861 51,238 - - 8,756,178	71,140 174,348 172,133 80,934 - - 9,791,288
	27,975,636	(18,414,138)	9,561,498	10,289,843

6 Government remittances

Government remittances consist of amounts required to be paid to government authorities and are recognized when the amounts become due. In respect of government remittances, 40,000 (2021 - 3354,220) is included within accounts payable and accrued liabilities.

Notes to Consolidated Financial Statements

March 31, 2022

7 Child Health Research Fund

				15-month period ended March 31, 2022 \$ (note 2)	Year ended December 31, 2020 \$
	Pediatric Research Fund \$	Research Facilities Building Fund \$	Research Facilities Equipment Fund \$	Total \$	Total \$
Revenue Funds received	1,067,891	-	-	1,067,891	1,067,933
Expenses Grants in aid of research	1,067,891	-	-	1,067,891	1,067,933
Deficiency of revenue over expenses	-	-	-	-	-
Fund balance – Beginning of year	9,444,724	505,716	-	9,950,440	9,950,440
Interfund transfers		(13,482)	-	(13,482)	
Fund balance – End of year	9,444,724	492,234	-	9,936,958	9,950,440

Notes to Consolidated Financial Statements

March 31, 2022

8 Funds Invested in Capital Assets

			15-month period ended March 31, 2022 \$ (note 2)	Year ended December 31, 2020 \$
	Research \$	Other \$	Total \$	Total \$
Fund balance – Beginning of year Purchase of capital assets	10,214,643	75,200	10,289,843	11,103,450
– net	139,931	361,142	501,073	141,253
Amortization of capital	10,354,574	436,342	10,790,916	11,244,703
assets – net	1,229,418	-	1,229,418	954,860
Fund balance – End of year	9,125,156	436,342	9,561,498	10,289,843

9 Allocation of expenses

The Foundation has allocated certain administrative expenses to indirect expenses and grants in aid of research based on the proportionate amount of time spent on indirect fundraising and research activities.

	15-month period ended March 31, 2022 \$ (note 2)	Year ended December 31, 2021 \$
Indirect expenses	123,702	96,900

10 Risk management

The Foundation manages risk and risk exposures by applying policies approved by the Board.

Credit risk

Credit risk is the risk that one party to a financial instrument fails to discharge an obligation and causes financial loss to another party. The Foundation is exposed to credit risk in its receivables and investments. The Foundation has an investment committee and policy which restricts the investing activities to quality investments in select market indices. Equity and fixed income securities are held in pooled funds. The Foundation, in the normal course of operations, is exposed to credit risk from its accounts receivables. The short-term nature of these receivables mitigates this risk.

Notes to Consolidated Financial Statements

March 31, 2022

Interest rate risk

Interest rate risk refers to the adverse consequences of interest rate fluctuations on the Foundation's cash flows, financial position and revenue. Certain of the Foundation's investments are subject to changes in interest rates.

Market rate risk

• Currency risk

Currency risk is the risk that the fair value or future cash flows of the investment in pooled funds will fluctuate as a result of changes in foreign exchange rates of investments held. The investments in pooled funds consist of approximately 35% foreign equities that are subject to currency risk.

• Other price risk

The Foundation is exposed to other price risk as its investment in pooled funds and other equity investments is subject to market fluctuations.

Liquidity risk

Liquidity risk is the risk that the Foundation cannot meet its financial obligations associated with financial liabilities in full. The Foundation expects to be able to meet its financial obligations in the foreseeable future.

During the year, the Foundation applied for and received wage subsidies in the amount of 381,739 (2020 – 452,640) which have been recorded as other revenue.

11 Interfund transfers

During the year, certain amounts were reallocated between funds to more appropriately reflect the terms of reference for each of these funds.

12 Commitments

There are commitments to fund program support to the Child Health Program and the Flouro Lab at the Children's Hospital, as well as various external research grants through the Children's Hospital Research Institute. The commitments for the next three years are as follows:

	\$
2023	918,750
2024	446,250
2025	46,250
	1,411,250

Notes to Consolidated Financial Statements

March 31, 2022

13 Pledges

The following pledges have been received by the Foundation but not recorded in these consolidated financial statements. The pledged amounts are expected to be received as follows:

	Unrestricted Fund \$	Designated Fund \$	Total Fund \$
2023 2024 2025 2026	17,000 15,000 7,500	2,422,900 1,008,000 452,500 155,000	2,439,900 1,023,000 460,000 155,000
	39,500	4,038,400	4,077,900